MedTrace Logo

Direct Pulp Capping Agent on Human Pulp Tissue

NCT06435065 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-05-30

No results posted yet for this study

Summary

This in- vivo study was conducted to evaluate the response of human pulp tissue following direct pulp capping using four different pulp capping agents in premolars scheduled for extraction in patients undergoing orthodontic treatment.

Conditions

  • Reversible Pulpitis

Interventions

DRUG

Biodentine

DIRECT PULP CAPPINGWILL BE DONE USING BIODENTINE

DRUG

Mineral Tri-Oxide Aggregate

DIRECT PULP CAPPINGWILL BE DONE USING MTA

DRUG

THERACAL LC

DIRECT PULP CAPPINGWILL BE DONE USING THERACAL LC

DRUG

TRISTRONTIUM ALUMINATE

DIRECT PULP CAPPINGWILL BE DONE USING TRISTRONTIUM ALUMINATE

Sponsors & Collaborators

  • DR SURINDER SACHDEVA

    lead OTHER

Principal Investigators

  • surinder sachdeva, mds · professor

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
25 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-04-01
Primary Completion
2024-06-30
Completion
2024-07-31

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06435065 on ClinicalTrials.gov